Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03287908 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 174
- Enrollment target
NCT03287908 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 174 participants.
The verdict
NCT03287908, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 174 participants
- Enrollment target
Study Summary
The primary purpose of the phase 1 part of the study is to evaluate safety and tolerability of AMG 701 monotherapy to identify the RP2D for AMG 701 monotherapy followed by a dose-confirmation part to gather further safety data for AMG 701 monotherapy at the RP2D in adult subjects with relapsed/refractory multiple myeloma (RRMM). In addition, this study will include a sequential dose exploration part to identify the RP2D of AMG 701 in combination with pomalidomide, with and without dexamethasone (AMG 701-P+/-d). Phase 2 will consist of the dose-expansion part to gain further efficacy and safety experience with AMG 701 monotherapy in adult subjects with RRMM.
Interventions
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG AMG 701
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2017-11-13 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03287908
The ClinicalTrials.gov registry entry for NCT03287908 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT03287908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03287908 about?
NCT03287908 is a clinical study titled "A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma". The primary purpose of the phase 1 part of the study is to evaluate safety and tolerability of AMG 701 monotherapy to identify the RP2D for AMG 701 monotherapy followed by a dose-confirmation part to gather further safety data for AMG 701 monotherapy at the RP2D in adult subjects with relapsed/refra...
What is the current status of trial NCT03287908?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2017-11-13. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT03287908?
The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), AMG 701 (DRUG).
Who is sponsoring clinical trial NCT03287908?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.